Trileptal

(oxcarbazepine)
Trileptal (oxcarbazepine); not controlled
Full Prescribing Information
DailyMed Drug Information
Summary
Trileptal is a sodium channel blocking antiepileptic, supplied as tablets and oral suspension, approved only for partial seizures: monotherapy from 4 years, adjunctive from 2 years. It carries no psychiatric indication at any age, so use for aggression, mood dysregulation or impulse control is entirely off-label. Its defining safety issue is hyponatremia, common enough to require scheduled sodium checks. Not controlled; brand and generic.
Forms & Strengths
Tablets: 150 mg, 300 mg, 600 mg
Oral suspension: 300 mg/5 mL
Extended-release tablets: 150 mg, 300 mg, 600 mg
Dosing
Age:
Partial seizures, monotherapy: 4 y/o and older
Partial seizures, adjunctive: 2 y/o and older
Psychiatric and behavioural use: no approved age; entirely off-label
Onset: 2 to 4 weeks, the time titration takes to reach target
Duration: continuous with twice-daily dosing
Initial Dose:
Pediatric monotherapy, 4 to 16 y/o: 8 to 10 mg/kg/day in two divided doses
Pediatric adjunctive, 2 to 16 y/o: 8 to 10 mg/kg/day divided, generally not above 600 mg/day
Under 20 kg: 16 to 20 mg/kg/day may be considered
Adults, all uses: 600 mg/day in two divided doses
Titration:
Pediatric monotherapy initiation: 5 mg/kg/day every 3 days
Pediatric conversion to monotherapy: up to 10 mg/kg/day weekly
Pediatric adjunctive: reach target over 2 weeks, or 2 to 4 weeks under 4 y/o
Adults: up to 600 mg/day weekly; 300 mg/day every third day for monotherapy
Max Dose:
Pediatric adjunctive, 2 to under 4 y/o: 60 mg/kg/day
Adjunctive 4 to 16 y/o: 900 mg/day at 20 to 29 kg, 1200 mg/day at 29.1 to 39 kg, 1800 mg/day above 39 kg
Monotherapy maintenance: 600 to 900 mg/day at 20 kg, up to 1500 to 2100 mg/day at 70 kg
Adults: 2400 mg/day, which most patients cannot tolerate
Considerations: All dosing is twice daily. Halve the starting dose to 300 mg/day and titrate slowly if creatinine clearance is under 30 mL/min; no adjustment for mild to moderate hepatic impairment.
Pharmacology
Mechanism: Blocks voltage-gated sodium channels, stabilising hyperexcited membranes; no demonstrated interaction with brain neurotransmitter or modulator receptors
Delivery / Release: immediate-release, completely absorbed, median Tmax 4.5 hours; with or without food
Metabolism: prodrug converted to the active 10-monohydroxy derivative (MHD); half-life 2 hours parent, 9 hours MHD, 19 hours if creatinine clearance is under 30 mL/min
Pharmacogenomics: HLA-B*1502 carriers risk Stevens-Johnson syndrome and toxic epidermal necrolysis. Test before starting in at-risk ancestry; avoid unless benefit clearly outweighs risk.
Class Positioning: like carbamazepine but with much less enzyme induction; hyponatremia is more frequent, not less. Adjunct to an ADHD regimen (Concerta, Strattera, Qelbree), never a replacement.
Indications
Partial Seizures, monotherapy (ICD-10: G40.1, G40.2): patients 4 y/o and older, and adults
Partial Seizures, adjunctive therapy (ICD-10: G40.1, G40.2): patients 2 y/o and older, and adults
No other approved indication exists, psychiatric or otherwise, at any age.
Off-Label Uses
Aggression, irritability and mood dysregulation (ICD-10: F90.x, F91.x): limited data. Risperidone (Risperdal) has moderate graded evidence here; oxcarbazepine has none. (AHRQ 2017)
Where the evidence does not support use:
Pediatric bipolar disorder (ICD-10: F31.x): insufficient; the carbamazepine analogy is pharmacological, not evidential.
Neuropathic pain, trigeminal neuralgia (ICD-10: G50.0, M79.2): insufficient; no pain indication at any age.
Generalized seizures (ICD-10: G40.3): insufficient and potentially harmful; can worsen some generalized epilepsies.
Contraindications & Warnings
Class warning, suicidal behaviour and ideation: antiepileptics roughly double the risk (adjusted RR 1.8, 95% CI 1.2 to 2.7), from week one, in every indication.
Contraindicated: known hypersensitivity to oxcarbazepine or any component.
Use with caution:
Prior carbamazepine hypersensitivity: 25% to 30% cross-react. Ask directly.
Ancestry in a high HLA-B*1502 frequency population, for Stevens-Johnson syndrome and toxic epidermal necrolysis risk.
Any other sodium-lowering drug: thiazides, SNRIs, drugs causing inappropriate ADH secretion.
Creatinine clearance under 30 mL/min: halve the starting dose; MHD half-life roughly doubles.
Hormonal contraception in an adolescent, because oxcarbazepine reduces its effectiveness.
Pregnancy or possible pregnancy, because oxcarbazepine is likely a human teratogen.
Screen before starting:
Baseline serum sodium; a later result cannot be interpreted without it.
Prior reaction to carbamazepine, asked as a direct question.
Ancestry, to decide whether HLA-B*1502 testing is indicated first.
Renal function; the medication list for sodium-lowering drugs and hormonal contraception.
Baseline mood and any history of suicidal ideation.
Drug Interactions
Hormonal contraceptives (oral, patch, ring): effectiveness is reduced. Arrange an alternative or added method before the first dose.
Other antiepileptics (carbamazepine, phenytoin, phenobarbital): mutual changes in exposure above 1200 mg/day. Check their levels through titration and at any dose change.
Calcium antagonists (felodipine, verapamil): exposure is altered. Recheck blood pressure after any change.
Other sodium-lowering drugs (thiazides, SSRIs, SNRIs, desmopressin, carbamazepine): additive hyponatremia. Check sodium 2 to 4 weeks after starting and at any dose change.
Laboratory tests: T4 falls without T3 or TSH change. Read an isolated low T4 as a drug effect, not hypothyroidism.
Administration
Give twice daily at roughly 12-hour intervals. The extended-release oxcarbazepine product is a separate NDA and must not be substituted milligram for milligram.
May be taken with or without food.
Use the oral suspension for weight-based pediatric dosing rather than splitting tablets.
The suspension is 60 mg/mL: divide the milligram dose by 60 for millilitres.
Shake the suspension; measure with a calibrated oral syringe, never a kitchen spoon.
Do not stop abruptly. See Discontinuation & Taper.
Side Effects
Common (at least 5%, above placebo): dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, abnormal gait
Serious:
Hyponatremia: sodium below 125 mmol/L in 2.5% of treated patients, usually asymptomatic. Reduce the dose or stop.
Anaphylaxis and angioedema of the larynx, glottis, lips or eyelids: stop and never rechallenge.
Stevens-Johnson syndrome and toxic epidermal necrolysis, median onset 19 days. Stop for any rash.
DRESS: fever, rash or lymphadenopathy with organ involvement. Discontinue unless another cause is established.
Dose-related psychomotor slowing, impaired concentration, speech problems, ataxia and gait disturbance.
Pancytopenia, agranulocytosis and leukopenia, rare: consider discontinuation.
Monitoring & Labs
Serum sodium: baseline, 2 to 4 weeks after starting, after every dose increase, at 3 months, then at least every 6 months; also 2 to 4 weeks after adding any sodium-lowering drug.
Serum sodium, unscheduled: for nausea, malaise, headache, lethargy, confusion, obtundation, or rising seizure frequency. Act before 125 mmol/L.
Suicidality and mood: at 1 week, 1 month, every dose change, and each routine visit thereafter.
Skin: ask about rash at every visit for the first 3 months; the family reports any rash the same day.
Cognitive and motor function: ask family and school about concentration, sleepiness and falls at each dose increase and every 6 months.
Contraception review: every visit, in any adolescent who could become pregnant.
Discontinuation & Taper
Withdraw gradually, per the label, to minimise increased seizure frequency. This holds even for off-label behavioural use.
Converting to another antiepileptic: withdraw over 3 to 6 weeks while the replacement reaches target over 2 to 4 weeks.
Stop permanently, no rechallenge, for anaphylaxis, angioedema or any serious dermatological reaction.
Discontinue for DRESS unless an alternative cause is established.
Reduce or stop for clinically significant hyponatremia; sodium normalises within a few days.
Drug holidays are not appropriate for either use.
Pregnancy & Lactation
Pregnancy: No adequate controlled studies; the label states oxcarbazepine is likely a human teratogen. Use only if benefit justifies risk.
Pregnancy, dosing: plasma MHD falls through pregnancy and returns after delivery; monitor seizure control across pregnancy and postpartum.
Lactation: milk-to-plasma ratio 0.5; levels low, adverse effects not expected beyond 2 months. Monitor infant drowsiness, weight gain, milestones. (LactMed 2024)
Exposure Registry: North American Antiepileptic Drug Pregnancy Registry, 1-888-233-2334; the patient enrolls herself.
Counseling Points
Counsel the family on:
This being a seizure medicine; behavioural use is off-label, with no approved dose ladder.
The sodium blood test schedule, done even when the child feels well; most affected children have no symptoms.
Reporting any rash the same day; name blistering, peeling and mouth or eye sores.
Sleepiness, unsteadiness and double vision being dose-related; report after an increase.
Never stopping suddenly, even if it seems to be doing nothing: that can trigger seizures.
For an adolescent who could become pregnant: less reliable hormonal birth control, likely fetal harm.
Advise them to call for:
Blistering or peeling skin, or mouth, eye or genital sores, immediately.
Swelling of the lips, tongue, eyelids or throat, or trouble breathing.
Fever with swollen glands, with or without rash.
Headache with unusual sleepiness, confusion, unsteadiness, or more frequent seizures.
New or worsening talk of self-harm, or a sudden mood change.
Unusual bruising, bleeding, or repeated infections.
References
DailyMed. Trileptal (oxcarbazepine) tablets prescribing information. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33af9350-95f3-384e-e054-00144ff88e88
LactMed. Oxcarbazepine. Drugs and Lactation Database, National Institute of Child Health and Human Development. 2024. https://www.ncbi.nlm.nih.gov/books/NBK501243/
AHRQ. First- and second-generation antipsychotics in children and young adults: systematic review update. Comparative Effectiveness Review No. 184. 2017. https://www.ncbi.nlm.nih.gov/books/NBK442344/
FDA. National Drug Code Directory, openFDA. Queried by generic name oxcarbazepine. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22oxcarbazepine%22&limit=1000